Antiplatelet effects of oral diltiazem, propranolol, and their combination

M. E. Ring, J. J. Corrigan, Paul E Fenster

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

1. The antiplatelet effects of a single oral dose of the calcium entry blocker diltiazem (60 mg), the β-adrenoceptor blocker propranolol (40 mg), and their combination were studied in five healthy subjects. 2. Platelet aggregation and ATP release induced by adrenaline and ADP and ADP induced platelet thromboxane A2 generation were significantly inhibited (P < 0.05) by either diltiazem or propranolol, although propranolol tended to have greater inhibitory effects on platelet function than diltiazem that did not reach statistical significance. 3. Combination therapy resulted in additive antiplatelet effects that were significantly (P < 0.05) greater than either drug alone. 4. These data indicate that combined administration of a calcium entry blocker and a β-adrenoceptor blocker results in additive inhibitory effects on platelet fuction. These effects may mediate part of the therapeutic efficacy of combination therapy in patients with coronary artery disease.

Original languageEnglish (US)
Pages (from-to)615-620
Number of pages6
JournalBritish Journal of Clinical Pharmacology
Volume24
Issue number5
StatePublished - 1987

Fingerprint

Diltiazem
Propranolol
Blood Platelets
Adenosine Diphosphate
Adrenergic Receptors
Calcium
Thromboxane A2
Platelet Aggregation
Epinephrine
Coronary Artery Disease
Healthy Volunteers
Therapeutics
Adenosine Triphosphate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antiplatelet effects of oral diltiazem, propranolol, and their combination. / Ring, M. E.; Corrigan, J. J.; Fenster, Paul E.

In: British Journal of Clinical Pharmacology, Vol. 24, No. 5, 1987, p. 615-620.

Research output: Contribution to journalArticle

@article{0e934c1438ae45f7ad6214a92a8852a9,
title = "Antiplatelet effects of oral diltiazem, propranolol, and their combination",
abstract = "1. The antiplatelet effects of a single oral dose of the calcium entry blocker diltiazem (60 mg), the β-adrenoceptor blocker propranolol (40 mg), and their combination were studied in five healthy subjects. 2. Platelet aggregation and ATP release induced by adrenaline and ADP and ADP induced platelet thromboxane A2 generation were significantly inhibited (P < 0.05) by either diltiazem or propranolol, although propranolol tended to have greater inhibitory effects on platelet function than diltiazem that did not reach statistical significance. 3. Combination therapy resulted in additive antiplatelet effects that were significantly (P < 0.05) greater than either drug alone. 4. These data indicate that combined administration of a calcium entry blocker and a β-adrenoceptor blocker results in additive inhibitory effects on platelet fuction. These effects may mediate part of the therapeutic efficacy of combination therapy in patients with coronary artery disease.",
author = "Ring, {M. E.} and Corrigan, {J. J.} and Fenster, {Paul E}",
year = "1987",
language = "English (US)",
volume = "24",
pages = "615--620",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Antiplatelet effects of oral diltiazem, propranolol, and their combination

AU - Ring, M. E.

AU - Corrigan, J. J.

AU - Fenster, Paul E

PY - 1987

Y1 - 1987

N2 - 1. The antiplatelet effects of a single oral dose of the calcium entry blocker diltiazem (60 mg), the β-adrenoceptor blocker propranolol (40 mg), and their combination were studied in five healthy subjects. 2. Platelet aggregation and ATP release induced by adrenaline and ADP and ADP induced platelet thromboxane A2 generation were significantly inhibited (P < 0.05) by either diltiazem or propranolol, although propranolol tended to have greater inhibitory effects on platelet function than diltiazem that did not reach statistical significance. 3. Combination therapy resulted in additive antiplatelet effects that were significantly (P < 0.05) greater than either drug alone. 4. These data indicate that combined administration of a calcium entry blocker and a β-adrenoceptor blocker results in additive inhibitory effects on platelet fuction. These effects may mediate part of the therapeutic efficacy of combination therapy in patients with coronary artery disease.

AB - 1. The antiplatelet effects of a single oral dose of the calcium entry blocker diltiazem (60 mg), the β-adrenoceptor blocker propranolol (40 mg), and their combination were studied in five healthy subjects. 2. Platelet aggregation and ATP release induced by adrenaline and ADP and ADP induced platelet thromboxane A2 generation were significantly inhibited (P < 0.05) by either diltiazem or propranolol, although propranolol tended to have greater inhibitory effects on platelet function than diltiazem that did not reach statistical significance. 3. Combination therapy resulted in additive antiplatelet effects that were significantly (P < 0.05) greater than either drug alone. 4. These data indicate that combined administration of a calcium entry blocker and a β-adrenoceptor blocker results in additive inhibitory effects on platelet fuction. These effects may mediate part of the therapeutic efficacy of combination therapy in patients with coronary artery disease.

UR - http://www.scopus.com/inward/record.url?scp=0023589244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023589244&partnerID=8YFLogxK

M3 - Article

C2 - 3435691

AN - SCOPUS:0023589244

VL - 24

SP - 615

EP - 620

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 5

ER -